Kornimate/medical-research-clean huggingface dataset:
pet mri study in patients with cardiac sarcoidosis

Conditions: Inflammatory Cardiomyopathy; Sarcoidosis

Summary: myocarditis or inflammatory cardiomyopathy refers to inflammation of the heart muscle (the myocardium). sarcoidosis is a multisystem granulomatous disorder that may involve the heart, causing inflammation, and potentially resulting in complications including arrhythmia and sudden death. the objective of this study is to evaluate the diagnostic and prognostic significance of simultaneous combined 18f-fdg pet and cardiac mri imaging in the evaluation of inflammatory cardiomyopathies including cardiac sarcoidosis. combined pet/mri imaging may allow for detection and quantification of active myocardial inflammation as well as chronic fibrosis and scarring. results of this study may allow for earlier detection of cardiac inflammation when compared with methods in current clinical use, and may lead to better understanding of the disease processes contributing to adverse outcomes. elucidation of imaging findings associated with future adverse event risk may impact patient management such as providing an indication for pacemaker or defibrillator implantation, or escalation of medical therapy.

myocarditis or inflammatory cardiomyopathy refers to inflammation of the myocardium. sarcoidosis is a multisystem granulomatous disorder of unknown etiology, which can result in myocardial inflammation. approximately 5% of patients with sarcoidosis have clinically apparent cardiac involvement, yet autopsy series indicate that cardiac involvement is present in up to 25% of cases. this discrepancy suggests that cardiac sarcoidosis may be under-diagnosed in clinical practice. recent studies have demonstrated high diagnostic accuracy of both cardiac mri and 18f-labelled fluoro-2-deoxyglucose (fdg) pet for detection of cardiac involvement. however, cardiac mri may fail to identify areas of active inflammation even with fluid sensitive t2-weighted sequences. fasting 18f-fdg positron emission tomography (pet) has been shown to identify early cardiac sarcoidosis with relatively high sensitivity. to date, simultaneous pet/mri evaluation of cardiac inflammation and sarcoidosis has only been described in limited case reports. the objective of the proposed research is to evaluate the utility of simultaneous pet/mri imaging in patients with cardiac sarcoidosis and other inflammatory cardiomyopathies.

Eligibility criteria:
inclusion criteria: * the primary criterion for enrolment will be patients ≥18 years of age with known or suspected sarcoidosis or other inflammatory cardiomyopathy who are referred for clinically indicated 18f-fdg pet/ct imaging exclusion criteria: * standard cardiac mri contraindications include arrhythmia, claustrophobia, history of allergic reaction or other contraindication to gadolinium-based contrast agent, impaired renal function with egfr \< 60 ml/min/1.73m2, pregnancy, breast-feeding, or any other general contraindication to mri (pacemaker, cerebral aneurysm clips, shrapnel, etc).
open label, safety and efficacy study of qrx003 lotion in subjects with netherton syndrome

Conditions: Netherton Syndrome

Summary: to assess the safety, tolerability, and efficacy of qrx003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with netherton syndrome


Eligibility criteria:
inclusion criteria: * subject is a male or non-pregnant female at least 14 years of age. * females must be post-menopausal , surgically sterile , or use an effective method of birth control , for the duration of the study and for 3 months following completion of treatment. women of childbearing potential (wocbp) must have a negative urine pregnancy test (upt) at visit 1/screening and visit 2/baseline. * subject has a clinical diagnosis of ns and agrees to genetic testing at visit 1/screening for confirmation of ns diagnosis if the subject does not have test results confirming a spink5 mutation. * subject has ns lesions in the treatment area (i.e., arms or lower legs). * subject is in good general health and free of any disease state or physical condition that might impair evaluation of ns or exposes the subject to an unacceptable risk by study participation. * subject is on a stable treatment regimen including systemic therapy for ns prior to baseline that is expected to remain stable for the duration of the study exclusion criteria: * subject is pregnant, lactating, or is planning to become pregnant during the study. * subject has any skin pathology in the treatment area or condition that, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy. * subject has active cancer of any type excluding non-melanoma skin cancer outside of the treatment area. * subject has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled. * subject has evidence of active infection during screening, or serious infection within 30 days prior to visit 2/baseline. * subject has known human immunodeficiency virus, hepatitis b or c virus, or active or latent tuberculosis. * subject has used ultraviolet phototherapy within the treatment area within 4 weeks prior to visit 2/baseline. * subject has used topical prescription treatment in the treatment area within 2 weeks prior to visit 2/baseline. * subject has used any topical bland moisturizers/emollients in the treatment area within 24 hours prior to visit 2/baseline. * subject is currently enrolled in an investigational drug, biologic, or device study. * subject has used an investigational drug, biologic, or device treatment within 30 days prior to visit 2/baseline.
needle guiding robot for radiofrequency ablation: safety and efficacy study on hepatocellular carcinoma patients

Conditions: Carcinoma, Hepatocellular

Summary: the needle guiding robot helps targeting of radiofrequency ablation needles by matching computed tomography images and patients' bodies. actual insertion of needles will be performed by doctors. this study evaluates the safety and efficacy of needle targeting on patients with hepatocellular carcinoma.

a robotic system has been developed that includes a needle-path planning system and a needle-guiding robot arm with computed tomography (ct) guidance. the robot consists of robot base, 5-axis robot arm with guiding end-effector and path-planner. optical tracking system with a custom-designed registration jig is used for the spatial registration and validation. advantages of the robotic system would be accurate targeting with diverse angulation of the robot arm in ct-guided tumor ablation. furthermore, robotic intervention might potentially decrease procedure time and radiation exposure to patients. the purpose of this clinical trial with patients with hepatocelluar carcinoma is to assess the safety and efficacy of our ct-guided needle-guiding robot.

Eligibility criteria:
inclusion criteria: * patients with up to three hepatocellular carcinomas (hcc) with no single hcc larger than 3 cm * candidates for ct-guided radiofrequency ablation of hcc * child-pugh class a or b exclusion criteria: * patients with untreatable/unmanageable coagulopathy * patients who are allergic to ct contrast media * patients with vascular invasion or extrahepatic metastases
maxpire: study to evaluate axatilimab in participants with idiopathic pulmonary fibrosis (ipf)

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the study will evaluate the efficacy and safety of axatilimab in participants with ipf.


Eligibility criteria:
key inclusion criteria: * documented diagnosis of ipf per the 2018 american thoracic society (ats)/european respiratory society (ers)/japanese respiratory society (jrs)/latin american thoracic society clinical practice guideline (raghu 2018). * chest high-resolution computed tomography (hrct) performed within 12 months prior to first screening visit and according to the minimum requirements for ipf diagnosis by central review based on participant's hrct only (if no lung biopsy is available) or based on both hrct and lung biopsy (with application of the different criteria in either situation). if an evaluable hrct \ 6 months old, if in the opinion of the investigator their disease has progressed, an additional hrct may be obtained and reviewed for eligibility. * fvc ≥45% of predicted normal at screening visits. * forced expiratory volume in 1 second (fev1)/fvc ≥0.7 at screening visits. * dlco ≥30% and ≤90% of predicted, corrected for hemoglobin at first screening visit. key exclusion criteria: * abnormalities detected on electrocardiogram (ecg) of either rhythm or conduction that in the opinion of the investigator are clinical significant. participants with implantable cardiovascular devices (for example, pacemaker) affecting the qt interval time may be enrolled in the study based upon investigator judgment following cardiologist consultation if deemed necessary, and only after discussion with the medical monitor. * emphysema present on ≥50% of the hrct, or the extent of emphysema is greater than the extent of fibrosis, according to central review of the hrct. * interstitial lung disease associated with known primary diseases (for example, connective tissue disease, sarcoidosis and amyloidosis), exposures (for example, radiation, silica, asbestos, and coal dust), or drugs (for example, amiodarone). * participants who cannot meet protocol-specified baseline stability criteria. * acute ipf exacerbation within 3 months prior to screening. * receiving nintedanib in combination with pirfenidone * receiving systemic corticosteroids equivalent to prednisone \>10 milligrams (mg)/day or equivalent within 2 weeks prior to screening. * use of any of the following therapies within 4 weeks prior to screening and during the screening period, or planned during the study: imatinib, ambrisentan, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine a, tacrolimus, bosentan, methotrexate, inhaled treprostinil, phosphodiesterase-5 inhibitors, including sildenafil (unless for occasional use), prednisone at steady dose \>10 mg/day or equivalent, or other investigational therapy. * history of cigarette smoking or vaping within the previous 3 months. * female participant who is pregnant or breastfeeding. * previous exposure to study intervention or known allergy/sensitivity to study drug. * receiving an investigational treatment within 28 days of randomization. * inadequate iv access.
effect of intravenous dexamethasone before spinal anesthesia on post-cesarean section pain

Conditions: Cesarean Section

Summary: \*aim of the work this study aims to assess the efficacy of intravenous injection of dexamethasone prior to spinal anesthesia in reducing post-cesarean section pain in women undergoing cesarean section.

\*research hypothesis: in women undergoing cesarean section, intravenous injection of dexamethasone prior to spinal anesthesia may reduce post-cesarean section pain. \*research question: in women undergoing cesarean section, does injecting intravenous dexamethasone prior to spinal anesthesia reduce post-cesarean section pain?

Eligibility criteria:
* inclusion criteria: * a gestational age of 38 weeks or more and planned for elective cesarean section. * living fetus. * any number of previous cesarean section. * intact amniotic membranes. * no history of bleeding tendency. * exclusion criteria: * refuse to participate after counseling. * contraindication to spinal anesthesia (coagulopathy significant hypovolemia systemic or local sepsis - increased intracranial pressure - local anesthetic or fentanyl allergy). * high risk pregnancies as pre-eclampsia, any medical disorder (diabetes mellitus, cardiac disease or and thyroid disease). * contraindication to corticosteroids e.g. systemic fungal infection * steroid medication one week before the operation. * chronic pain or daily intake of analgesic. * abnormal placentation e.g. placenta previa. * intrauterine infection.

Keywords: intravenous dexamethasone spinal anesthesia post-cesarean section pain
patient education strategy for breast cancer patients during perioperative hospitalization stage

Conditions: Breast Carcinoma; Patient Education; Perioperative Care; Psychological Intervention

Summary: introduction breast cancer remains a leading global health concern, with significant psychological challenges during the perioperative period. traditional patient education focuses on disease management but often neglects emotional and cognitive needs. perioperative inpatients are relatively stable and have the time and mental space for deeper education and psychological support. this study evaluates the clinical significance of a medical humanities-based education strategy for breast cancer patients during hospitalization, aiming to enhance psychological resilience, treatment adherence, and quality of life. methods and analysis this prospective, non-randomized, open-label study will include female patients with early-stage breast cancer scheduled for surgery at fudan university shanghai cancer center. participants will be allocated to two cohorts: practical education group and mental enhanced group. the primary endpoint is psychological assessment at hospital discharge, including anxiety (gad-7), depression (phq-9), and sleep quality (isi). secondary endpoints include the proportion of patients opting for breast-conserving procedures, incidence of postoperative complications, long-term treatment adherence (mmas-8), patients' disease-coping resilience (cd-risc-10), and quality of life assessment (eortc qlq instruments) at 12-month follow-up. data collection and statistical analysis will be conducted using validated instruments and software, with significance set at p ≤0.05. ethics and dissemination approved by the fuscc ethics committee, all participants provide informed consent. results will be disseminated through international conferences and peer-reviewed journals. the study adheres to ethical guidelines, ensuring data confidentiality via encrypted platforms. authors declare no conflicts of interest, supported by shanghai municipal science and technology innovation action plan (24dz2303500). findings aim to optimize perioperative education strategies, addressing psychological and informational needs of breast cancer patients.


Eligibility criteria:
inclusion criteria: * more than 18 years old * female * patient with early-stage breast cancer with preoperative pathology confirming invasive breast carcinoma or ductal carcinoma in situ * no clinical or imaging evidence of distant metastasis * patients to receive breast surgery during hospitalizaiton (including mastectomy, breast conserving therapy, reconstrucion, etc.) * be able and willing to sign the informed consent form (icf) exclusion criteria: * patients with locally advanced breast cancer to receive neoadjuvant therapy * patients currently participating in other clinical trials, which may have impact on the participation in this trial * previous history of breast cancer (patients with ipsilateral recurrence after breast sparing surgery)

Keywords: breast carcinoma patient education educational comic psychological intervention hospitalization
improving participation of autistic children and adolescents in the habilitation process

Conditions: Autism Spectrum Disorders

Summary: this project aims to explore the impact of a survey-based and a meeting-based needs assessment models on 7 to 17 year old autistic children's participation in the needs assessment process at the initial reception when enrolled at a child and youth habilitation centre.

the increasing number of children diagnosed with autism spectrum disorder (asd) presents significant challenges for healthcare providers. research emphasizes the importance of involving children in their healthcare decisions. however, due to the complex nature of asd, characterized by differences in communication and social interaction, healthcare professionals struggle to adapt their services for these children. to address this issue, the present study compares two assessment methods for children with asd: one based on surveys and another based on meetings with healthcare professionals. in addition, supplementary information from the children's parents or guardians and healthcare providers will be gathered . data collection methods will include questionnaires, interviews, and analysis of individual habilitation plans. the goal is to recruit 120 children aged 7-17 diagnosed with asd but without intellectual disabilities, with half undergoing the survey-based assessment and the other half undergoing the meeting-based assessment.

Eligibility criteria:
inclusion criteria: * autism spectrum disorder exclusion criteria: * intellectual disability

Keywords: autism spectrum disorder patient participation needs assessment child adolescent parent
the effect of turmeric on new onset primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: the study was planned as 150 patients. patients who met early-onset dysmenorrhea criteria and who met the inclusion criteria; 150 patients were divided into 2 equal groups, and nsaid during the menstrual cycle, nsai + turmeric 1 gr oral powder form treatment was planned to be started in the other group. the pain frequency and severity before and after treatment were evaluated by visual analog scale and the two groups were compared.

there are scientific publications on the use of turmeric, which constitutes the hypothesis of our study, in branches such as cardiology, neurology, infertility and chest diseases due to its anti-inflammatory, anti-aging properties. the data are planned to be evaluated by the researchers using the spss(statistical package for the social sciences ) 17.0 program on computer. the responses of all groups to the vas scores are planned to be entered into the system by using the spss program before and after treatment. statistics (number, percentage, mean, standard deviation), chi-square and logistic regression analysis are used to compare categorical variables. chi-square test and mann whitney-u test are planned to be used in comparison between groups.when examining the difference between the groups, if the p value is less than 0.05, it is planned as a proof of significant difference.

Eligibility criteria:
inclusion criteria: 1. early-onset primary dysmenorrhea (definition: pain that begins in less than 6 months, is not accompanied by infection, begins on the first day of menstruation and ends on the last day of menstruation) 2. non-pregnant and breastfeeding patients 3. between 16-35 years old 4. no anatomic pathology or disease 5. lack of active infection 6. no history of drug use 7. bmi is less than 25 8. those who wish to participate in the study signed the consent form 9. smoking, non-alcoholic patients 10. patients who completed their treatment and came to the control 11. regular menstruation exclusion criteria: 1. presence of vaginal infection such as trichomonas vaginalis and candida albicans 2. patients who do not want to participate in the study 3. pregnant and nursing patients 4. be under 16 years or older than 30 years 5. systemic disease 6. smoking, alcohol consumption 7. bmi higher than 25 8. people with organic pelvic pathology (ovarian cyst, fibroids, polyps) 9. people with a history of drug use 10. patients who discontinue treatment and do not come to control 11. irregular menstruation 12. any history of contraindication to naproxen 13. turmeric allergy history

Keywords: new onset primary dysmenorrhea turmeric naproxen
role of fcγriiia and fcγriia receptor polymorphisms

Conditions: Upper Gingival Squamous Cell Carcinoma

Summary: hypothesis: cetuximab, an anti-egfr antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. actually, no predictive biomarkers of cetuximab antitumor activity are known in this setting. it has been shown recently that fcγriiia and fcγriia receptor polymorphisms played a role in antitumor activity of trastuzumab and cetuximab. the investigators therefore hypothesized that fcγriiia and fcγriia receptor polymorphisms may play a predictive role in cetuximab effectiveness in upper aerodigestive tract cancers with recurrence or metastatic disease that make them inaccessible to loco regional treatment.

hypothesis: cetuximab, an anti-egfr antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. actually, no predictive biomarkers of cetuximab antitumor activity are known in this setting. it has been shown recently that fcγriiia and fcγriia receptor polymorphisms played a role in antitumor activity of trastuzumab and cetuximab. we therefore hypothesized that fcγriiia and fcγriia receptor polymorphisms may play a predictive role in cetuximab effectiveness in upper aerodigestive tract cancers with recurrence or metastatic disease that make them inaccessible to loco regional treatment. this study is a multicentre prospective pharmacogenetic observational study, conducted on locally advanced and inoperable upper aerodigestive tract cancers.

Eligibility criteria:
inclusion criteria: * patient with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract * patient with loco-regional extension not readily treatable * 18 years * follow up in participant center * patient information and consent for study participation * patient presented in multidisciplinary meeting (rcp) in aquitaine and for whom a treatment containing cetuximab has been proposed * belong to a social security system exclusion criteria: * pregnancy * patient with psychological, social, family or geographical reason, who could not be treated or monitored regularly by study criteria, * patients deprived of liberty or under guardianship or who could not give consent for study participation * inclusion in another study

Keywords: upper aero-digestive tract tumours fcgr3a and fcgr2a receptor polymorphism cetuximab efficacy
chemoradiotherapy followed by surgery for advanced paranasal sinus cancer

Conditions: Paranasal Sinus Neoplasms

Summary: the purpose of this study is to determine the efficacy of concurrent chemotherapy and radiotherapy pre-operatively in patients with advanced paranasal sinus cancer. the main objectives of this study are: 1) to measure the rate of complete response to preoperative chemoradiation and 2) to study the efficacy of combining preoperative chemoradiation and surgery in terms of local control of the cancer two years post treatment.


Eligibility criteria:
inclusion criteria: * karnofsky performance score: \>= 60 * creatinin clearance \>= 50 ml/min or serum creatinine =\<1.5 mg/dl * total bilirubin, ast, alt =\< 1.5 x laboratory uln * anc \>= 2000/mm3, platelets \>= 100,000/mm3 * serum calcium within normal range * t3 or t4 state tumors of paranasal sinuses * squamous cell carcinoma, adenocarcinoma, high-grade mucoepidermoid carcinoma, sinonasal undifferentiated carcinoma exclusion criteria: * history of other malignancy in the last 3 years * other serious comorbidity that may significantly reduce the survival in next 5 years * pregnant or lactating women * history of radiation to the head and neck region * paranasal sinus tumor is recurrent after prior treatment * presence of cervical node metastasis * presence of distant metastasis * advanced nasopharyngeal malignancy with sphenoid or posterior ethmoid invasion